Viventia Biotech, Inc. (Viventia) is a biopharmaceutical company engaged in discovery and development of novel antibody based drugs for the treatment of cancer. The company is engaged in development of Vicinium drug a product used for the treatment of bladder cancer and VB6-845 product for the treatment of solid tumors. It is also engaged in development of pipeline of antibodies including onoclonal antibody. The key technologies of the company include, UnLock, isolation and identification of membrane-associated tumor markers, Fusogenics,Armed Antibodies, engineered antibody fragments (solid tumor penetration) and ImmunoMine, high-throughput antibody screening process. It has a GMP manufacturing, research development and operations campus in Winnipeg, Canada. The company is headquartered at Mississauga in Ontario the US.